SCHEMBL877952

SCHEMBL877952

O=C(O)CCC(S)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.48
ALDH1A1 P00352 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP1A2 P05177 1/20 0.48
TSHR P16473 1/20 0.48
CPA3 P15088 1/20 0.47
NAALAD2 Q9Y3Q0 1/20 0.46
FOLH1 Q04609 1/20 0.45
KEAP1 Q14145 1/20 0.43
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
GLA P06280 1/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL3192561 0.94 CYP2D6 (0.44) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
SCHEMBL3206596 0.91 ALDH1A1 (0.42) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
SCHEMBL3209366 0.91 ALDH1A1 (0.42) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
Glycerin SCHEMBL3214162 0.89 ALDH1A1 (0.41) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
Glycerin SCHEMBL3213893 0.89 ALDH1A1 (0.41) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
SCHEMBL877721 0.89 FFAR1 (0.50) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
SCHEMBL27944397 0.88 HDAC3 (0.47) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
Propylene Glycol SCHEMBL3212556 0.88 ALDH1A1 (0.40) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
SCHEMBL3204228 0.87 NAALAD2 (0.41) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR
SCHEMBL3215253 0.87 NAALAD2 (0.44) CYP2D6ALDH1A1CYP2C19CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619177-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP claimed
WO-2012038943-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO claimed
CN-115989455-A Lithographic printing plate precursor 爱克发胶印有限公司 2023-04-18 CN disclosed
CN-103415507-A 3-amino-pyridines as GPBAR1 agonists HOFFMANN LA ROCHE 2013-11-27 CN disclosed
EP-2619177-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038943-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed
US-20100029876-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND SHOWA DENKO K.K. (JP) 2010-02-04 US disclosed
EP-2030989-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING THIOL COMPOUND Showa Denko K.K. (JP) 2009-03-04 EP disclosed
WO-2002095044-A2 LIPASE CATALYZED ESTERIFICATION, TRANSESTERIFICATION, AND HYDROLYSIS OF ARYLTHIOLS AND ARYL-THIOESTERS MOLECULAR ELECTRONICS CORPORATION (US) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029876-A1 POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND TMT1A, CCNT1, MGMT CYP2D6 4344/4885ALDH1A1 124/4885CYP2C19 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.